TrialBMC cancer2015

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

Benoist Chibaudel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.